Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?

Recent evidence indicates that high epidermal growth factor receptor (EGFR) gene copy number evaluated by fluorescence in situ hybridization is an excellent predictive biomarker for response and survival benefit in patients with non–small cell lung cancer who receive epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Data on EGFR protein expression by immunohistochemistry as a selection marker are conflicting, although several studies showed that the treatment benefit was confined to EGFR-positive patients. Our studies and others showed that fluorescence in situ hybridization and immunohistochemistry were associated with the best predictive value. Expeditious validation of this information in prospective clinical trials with patient selection to first-line treatment is currently being done or planned by several cancer research groups worldwide.

[1]  F. Cappuzzo,et al.  Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[2]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[3]  M. Ladanyi,et al.  Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.

[4]  F. Cappuzzo,et al.  HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients , 2005, British Journal of Cancer.

[5]  Patricia L. Harris,et al.  Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Kevin Carroll,et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.

[7]  F. Hirsch,et al.  Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Shibata,et al.  Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Xin Li,et al.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Mayumi Ono,et al.  Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas , 2005, Clinical Cancer Research.

[12]  Elisa Rossi,et al.  Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Zhang,et al.  The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[15]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[16]  J. Baselga,et al.  Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Young Tae Kim,et al.  Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Takayuki Kosaka,et al.  Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Mermel,et al.  ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Michael Peyton,et al.  Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. , 2005, Cancer research.

[21]  G. Giaccone,et al.  Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Daniel Jones.  Anticancer drugs: To the rescue? , 2004, Nature Reviews Drug Discovery.

[23]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[24]  Chan Zeng,et al.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. J. Solan,et al.  Prognostic factors in non-small cell lung cancer. , 2003, Seminars in surgical oncology.

[26]  G. Scagliotti,et al.  Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. , 2003, Lung cancer.

[27]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M Paesmans,et al.  The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis , 2002, European Respiratory Journal.

[29]  Zhong Wen-zhao,et al.  Erlotinib in Lung Cancer - Molecular and Clinical Predictors of Outcome , 2006 .

[30]  V Torri,et al.  Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  A. Gasinska,et al.  Prognostic significance of epidermal growth factor receptor in surgically treated squamous cell lung cancer patients. , 2004, Folia histochemica et cytobiologica.